ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 795

Frequency and Clinical Associations of Rare Antibodies in a Large Connective Tissue Disease Cohort

Kristina E.N. Clark1, Corrado Campochiaro2, Lauren V. Host3, Alper Sari4, Svetlana I. Nihtyanova5, Carmen Fonseca6, Christopher P. Denton7 and Voon H. Ong8, 1Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 2Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, 3Department of Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 4Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 5Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 6UCL Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, 7University College London, London, United Kingdom, 8Division of Medicine, University College London, London, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: antibodies and scleroderma, Pulmonary Involvement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Sclerosis and Related Disorders – Clinical Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Connective tissue diseases (CTDs) are characterised by specific autoantibodies which are useful for diagnosis. Rare antibodies have been described in CTDs in several case series. We assessed the frequency and clinical features of CTD patients attending our centre, positive for at least one of these antibodies (Jo-1, PCNA, XR, PL-4, PL-7, PL-12, SRP, Ku, Mi-2, EJ, SL, PmScl, rRNP, Th/To, NuMa-1, OJ and hnRNP). Rare antibody was defined as an antibody found in less than 5% of our patient population.

Methods:

The immunology results for 5828 patients obtained over the past 17 years were analysed and patients with the rare antibodies were identified. Clinical data including diagnosis and frequency of organ involvement were obtained from medical records and patient review.

Results:

758 patients (12.5%) were positive for at least one rare antibodies. Clinical information confirming a diagnosis of a CTD was available for 514 patients. The most common rare antibody was PmScl (3.1%) and least common was OJ (0.01%). The majority of patients with rare autoantibodies demonstrated overlap syndromes (32.1%), the second most common diagnosis was scleroderma (SSc) (31.0%). The least common diagnosis was UCTD (1.1%).

Further analyses of major organ involvement by antibody subtype revealed 82.4% of PL-7+ patients had interstitial lung disease (ILD). ILD was also frequently seen in PL12+ (75%), Jo-1+ (70.8%), SRP+ patients (66.7%) and Mi-2 (57%). PCNA, NuMa1, OJ and hnRNP were not associated with ILD. Pulmonary arterial hypertension (PAH) was most frequently seen in XR+ patients (31.8%), followed by Th/To+ (25%) and Jo-1 (15.3%) patients. None of our patients with PL-12 developed PAH. Inflammatory myositis (IM) was found in all Jo1+ and SRP+ patients, and in the majority of PL-7+ (88.2%) patients. Inflammatory arthritis was more commonly seen in hnRNP+ (100%), PCNA+ (57.1%), SL+ (38.3%), and PL-12+ (33.3%) patients but not reported in EJ+, Mi-2+ and PL-4+ patients. Glomerulonephritis was reported in significant proportion of rRNP+ (60%), PCNA+ (42.9%), and PL-4+ (45.5%) patients. Scleroderma renal crisis was diagnosed in three (3.8%) SL+ patients.

Conclusion:

Our data from a large cohort of patients with CTDs suggest that rare antibodies associate with characteristic features, in particular ILD and inflammatory myositis. A majority of these patients fulfil the criteria for overlap syndrome and SSc.

We noted some associations not reported in current literature between these antibodies and fibrotic and vascular features of CTDs. In contrast to previous findings, ILD was frequently reported in our Mi-2+ patients. Anti XR has not previously been associated with PAH or ILD, whereas we noted a frequency of 31.8% and 40.9% respectively.

Given the rarity of these antibodies, it is important to understand the clinical impact they may have in risk stratifying our patients at diagnosis especially given the high proportion of patients with overlap CTD features.


Disclosure: K. E. N. Clark, None; C. Campochiaro, None; L. V. Host, Roche, 2,Australian Rheumatology Association (ARA), 2,Arthritis Australia, 2,ARA Western Australia, 2; A. Sari, None; S. I. Nihtyanova, None; C. Fonseca, None; C. P. Denton, Roche, Actelion, GlaxoSmithKline, Sanofi-Aventis, Inventiva, SCL Behring, Boehringer-Ingelheim, Bayer., 5; V. H. Ong, None.

To cite this abstract in AMA style:

Clark KEN, Campochiaro C, Host LV, Sari A, Nihtyanova SI, Fonseca C, Denton CP, Ong VH. Frequency and Clinical Associations of Rare Antibodies in a Large Connective Tissue Disease Cohort [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/frequency-and-clinical-associations-of-rare-antibodies-in-a-large-connective-tissue-disease-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frequency-and-clinical-associations-of-rare-antibodies-in-a-large-connective-tissue-disease-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology